AN INNOVATIVE APPLICATION
OF HEMATOPOIETIC STEM CELL EXPANSION FOR GENE THERAPY
IN A NUTSHELL
The technological breakthrough of X-PAND is to clarify the identity of ex-vivo expanded hematopoietic stem cells (HSC) through iterative cell sorting, multiomics single cell profiling and to apply this knowledge to a state-of-the-art toolbox of genetic engineering technologies.
This innovative multidisciplinary procedure would maximize the chances of delivering a safer next-generation hematopoietic stem cell-based gene therapy product, extending its application to new disease contexts.
WORKPLAN
WP1
WP2
Novel in vitro multiomic approaches to replace in vivo animal models
WP3
Genome and epigenome integrity and HSC response to editing
WP4
Optimized genetic correction of HSCs for cancer-prone monogenic diseases and novel “gain-of-function” engineering of HSC against cancer
WP5
Multiomics HSC readouts: bioinformatic data integration & storage
WP6
Exploitation, dissemination & communication
WP7
Management and scientific coordination
WP8
Portfolio Activities
CONSORTIUM
Ospedale San Raffaele
Milan, Italy
Universitätsklinikum Freiburg
Freiburg, Germany
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas
Madrid, Spain
Fundación Miguel Servet
Pamplona, Spain
Universidad de Navarra
Pamplona, Spain
Lausanne University Hospital
Lausanne, Switzerland
Università Vita-Salute San Raffaele
Milan, Italy
NEWS
X-PAND CONSORTIUM IS NOW ON LINKEDIN AND ON TWITTER!
We are glad to launch the new X-PAND consortium profiles, a new project funded by European Innovation Council…
X-PAND: A NEW MULTI-CENTRIC PROJECT ON GENE THERAPY
Ospedale San Raffaele announces the launch of the four-year international, multi-centric project X-PAND (GA 101070950), funded with approximately 4 million euros